Skip to content
MARKETS / BALCAO / BSPK
BALCAO · PHARMACEUTICAL PREPARATIONS

Bespoke Extracts, Inc. BSPK

14 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.1M
▲ 42.3% YoY
$-1.0M
$-889,802
In brief

What this company does

The Company has one wholly-owned subsidiary, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”). Currently, Bespoke owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado. Since the change in management and control of the Company that occurred in November 2021, we now primarily operate within the regulated cannabis industry through Bespoke Colorado. We are a licensed operator in the recreational adult-use cannabis market in Colorado where we offer, and plan to expand, a portfolio of adult-use brands and products. As of the date of the filing of this report, we have 8 full-time employees.

Written from the business description in Bespoke Extracts, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 21 April 2025. Every sentence was checked against that document before publication.

Growth
USD 1.1M
Revenue, FY2024 · full 14-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.1 · Net income -1.0
1M2M-4M20112013201520172019202120232024
Compound annual growth
+215.5%
+78.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +78.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−93 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -89.0% · Net -92.8%
-50000%-100000%20112013201520172019202120232024
ROE
FY2022 · ROE -624.7%
-200%-400%-600%20112013201520172019202120232024

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -0.9
-0.4M-0.8M20112013201520172019202120232024
Net buybacks $ Dividends $
FY2020 · Dividends — · Net buybacks 27500.0
10000200002020

Total assetsUSD 359,088.00
EquityUSD -2.1M
CashUSD 60,305.00
Gross debtUSD 310,000.00
Net debtUSD 249,695.00
Current ratio0.15×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.0·0.00.0·······
Operating income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0············
Income tax $B··············
Net income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0·−0.0−0.0··········
EPS, diluted $−0.10−0.15−0.44−0.19−0.040.04−0.21−0.48−0.13−0.30−0.25−0.090.000.00
Dividend / sh $··············
Payout %··············
ROE %··−624.7−130.8····−531.3−142.9−54.8−45.8−94.5−248.7
Shares out B0.010.010.010.010.190.080.040.030.000.000.000.010.330.34

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 60 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 35 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2011

Share this section

Download image